Hydroxysafflor yellow A ameliorates lipopolysaccharide-induced acute lung injury in mice via modulating toll-like receptor 4 signaling pathways

International Immunopharmacology

Volumn 23, Issue 2, 2014, Pages 649-657

  Liu, Ya Li ^a   Liu, Ya Juan ^b   Liu, Yang ^a   Li, Xue Song ^a   Liu, Shuan Hu ^a   Pan, Yong Gui ^a   Zhang, Jian ^a   Liu, Qiang ^a   Hao, Ying Yan ^a  

^a Tangshan Gongren Hospital   (China)

^b Department of Ultrasonography Tangshan City Ninth Hospital   (China)

Author keywords

Acute lung injury; Hydroxysafflor yellow A; Lipopolysaccharide; Toll like receptor 4

Indexed keywords

BETA INTERFERON; DEXAMETHASONE; HYDROXYSAFFLOR YELLOW A; I KAPPA B KINASE ALPHA; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MYELOID DIFFERENTIATION FACTOR 88; MYELOPEROXIDASE; PROTEIN; SAFFLOWER EXTRACT; STRESS ACTIVATED PROTEIN KINASE; TIR DOMAIN CONTAINING ADAPTER INDUCING INTERFERON BETA; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CHALCONE; CYTOKINE; ENDOTOXIN; ENDOTOXIN, ESCHERICHIA COLI; QUINONE DERIVATIVE; TLR4 PROTEIN, MOUSE;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; HISTOPATHOLOGY; INFLAMMATION; INFLAMMATORY CELL; LUNG EDEMA; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMICAL STRUCTURE; CHEMICALLY INDUCED; CHEMISTRY; CHINESE MEDICINE; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

ACUTE LUNG INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE FLUID; CHALCONE; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; MALE; MEDICINE, CHINESE TRADITIONAL; MICE, INBRED ICR; MOLECULAR STRUCTURE; QUINONES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84913590465     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.10.018     Document Type: Article

References (37)

1. Ware LB, Matthay MA. Medical progress - the acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49.
2. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007;369:1553-64.
3. Dushianthan A, Cusack R, Goss V, Postle AD, Grocott MP. Clinical review: exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome - where do we go from here? Crit Care 2012;16:238.
4. Wang N, Liu X, Zheng X, Cao H, Wei G, Zhu Y, et al. Ulinastatin is a novel candidate drug for sepsis and secondary acute lung injury, evidence from an optimized CLP rat model. Int Immunopharmacol 2013;17:799-807.
5. Melo AC, Valenca SS, Gitirana LB, Santos JC, Ribeiro ML, Machado MN, et al. Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury. Int Immunopharmacol 2013;17:57-64.
6. Atabai K, Matthay MA. The pulmonary physician in critical care. 5: Acute lung injury and the acute respiratory distress syndrome: definitions and epidemiology. Thorax 2002;57:452-8.
7. Rojas M, Woods CR, Mora AL, Xu JG, Brigham KL. Endotoxin-induced lung injury in mice: structural, functional, and biochemical responses. Am J Physiol Lung Cell 2005;288:L333-41.
8. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008;133:235-49.
9. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006;117:979-87.
10. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-8.
11. Smyth K, Garcia K, Sun Z, Tuo W, Xiao Z. TLR agonists are highly effective at eliciting functional memory CTLs of effector memory phenotype in peptide immunization. Int Immunopharmacol 2013;15:67-72.
12. Yang Z, Yang J, Jia Y, Tian Y, Wen A. Pharmacokinetic properties of hydroxysafflor yellow A in healthy Chinese female volunteers. J Ethnopharmacol 2009;124:635-8.
13. Tian J, Li G, Liu Z, Fu F. Hydroxysafflor yellow A inhibits rat brain mitochondrial permeability transition pores by a free radical scavenging action. Pharmacology 2008;82:121-6.
14. Ji DB, Zhang LY, Li CL, Ye J, Zhu HB. Effect of Hydroxysafflor yellow A on human umbilical vein endothelial cells under hypoxia. Vascul Pharmacol 2009;50:137-45.
15. Wu Y, Wang L, Jin M, Zang B-x. Hydroxysafflor yellow A alleviates early inflammatory response of bleomycin-induced mice lung injury. Biol Pharm Bull 2012;35:515-22.
16. Pan Y, Zheng DY, Liu SM, Meng Y, Xu HY, Zhang Q, et al. Hydroxysafflor yellow A attenuates lymphostatic encephalopathy-induced brain injury in rats. Phytother Res PTR 2012;26:1500-6.
17. Wei X, Liu H, Sun X, Fu F, Zhang X, Wang J, et al. Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action. Neurosci Lett 2005;386:58-62.
18. Bezerra-Santos CR, Vieira-de-Abreu A, Vieira GC, Filho JR, Barbosa-Filho JM, Pires AL, et al. Effectiveness of Cissampelos sympodialis and its isolated alkaloid warifteine in airway hyperreactivity and lung remodeling in a mouse model of asthma. Int Immunopharmacol 2012;13:148-55.
19. Liang D, Sun Y, Shen Y, Li F, Song X, Zhou E, et al. Shikonin exerts anti-inflammatory effects in a murine model of lipopolysaccharide-induced acute lung injury by inhibiting the nuclear factor-kappaB signaling pathway. Int Immunopharmacol 2013;16:475-80.
20. Gao M, Chen L, Yu H, Sun Q, Kou J, Yu B. Diosgenin down-regulates NF-kappaB p65/p50 and p38MAPK pathways and attenuates acute lung injury induced by lipopolysaccharide in mice. Int Immunopharmacol 2013;15:240-5.
21. Oygucu SE, Ozbudak IH, Akcan AB, Coskun M, Ozel D, Ozbilim G, et al. Effects of high-dose intravenous immunoglobulin on lipopolysaccharide-induced acute lung injury. Int Immunopharmacol 2014;21:51-5.
22. Siddikuzzaman, Grace VM. Inhibition of metastatic lung cancer in C57BL/6 mice by liposome encapsulated all trans retinoic acid (ATRA). Int immunopharmacol 2012;14:570-9.
23. Bouwmeester T, Bauch A, Ruffner H, Angrand P-O, Bergamini G, Croughton K, et al. A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nat Cell Biol 2004;6:97-105.
24. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001;107:1529-36.
25. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta (BBA) Mol Cell Res 2011;1813:878-88.
26. Baccala R, Welch MJ, Gonzalez-Quintial R, Walsh KB, Teijaro JR, Nguyen A, et al. Type I interferon is a therapeutic target for virus-induced lethal vascular damage. Proc Natl Acad Sci U S A 2014;111:8925-30.
27. Yilmaz O, Karaman M, Bagriyanik HA, Firinci F, Kiray M, Turkeli A, et al. Comparison of TNF antagonism by etanercept and dexamethasone on airway epithelium and remodeling in an experimental model of asthma. Int Immunopharmacol 2013;17:768-73.
28. Yin H, Li X, Yuan B, Zhang B, Hu S, Gu H, et al. Heme oxygenase-1 ameliorates LPS-induced acute lung injury correlated with downregulation of interleukin-33. Int Immunopharmacol 2011;11:2112-7.
29. Kim TW, Joh EH, Kim B, Kim DH. Ginsenoside Rg5 ameliorates lung inflammation in mice by inhibiting the binding of LPS to toll-like receptor-4 on macrophages. Int Immunopharmacol 2012;12:110-6.
30. Yuan S, Huang S, Zhang W, Wu T, Dong M, Yu Y, et al. An amphioxus TLR with dynamic embryonic expression pattern responses to pathogens and activates NF-κB pathway via MyD88. Mol Immunol 2009;46:2348-56.
31. Jarrar D, Kuebler JF, Rue III LW, Matalon S, Wang P, Bland KI, et al. Alveolar macrophage activation after trauma-hemorrhage and sepsis is dependent on NF-κB and MAPK/ERK mechanisms. Am J Physiol Lung Cell 2002;283:L799-805.
32. Schwartz MD, Moore EE, Moore FA, Shenkar R, Moine P, Haenel JB, et al. Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 1996;24:1285-92.
33. Nolan GP, Ghosh S, Liou H-C, Tempst P, Baltimore D. DNA binding and IκB inhibition of the cloned p65 subunit of NF-κB, a 〈i〉 rel 〈/i〉 -related polypeptide. Cell 1991;64:961-9.
34. Jeyaseelan S, Chu HW, Young SK, Freeman MW, Worthen GS. Distinct roles of pattern recognition receptors CD14 and Toll-like receptor 4 in acute lung injury. Infect Immun 2005;73:1754-63.
35. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003;301:640-3.
36. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003;4:1144-50.
37. Mages J, Dietrich H, Lang R. A genome-wide analysis of LPS tolerance in macrophages. Immunobiology 2008;212:723-37.